Spark Therapeutics Tops $1 Billion in Financing with Latest Public Offering

September 1, 2017: By Joan McKenna

SparkSpark Therapeutics has raised about $380.4 million in a public offering of 5.3 million shares of common stock, the Philadelphia gene therapy company announced Aug. 9.

The company says it has now secured $1 billion in total financing. Spark was founded in March 2013.

It is developing gene therapies that address inherited retinal diseases, neurodegenerative diseases, and diseases that can be addressed by targeting the liver, such as hemophilia.

Spark’s most advanced candidate, with the proposed trade name Luxturna (voretigene neparvovec), is currently under priority review with the US FDA for the treatment of biallelic RPE65-mediated inherited retinal disease. The company has filed for marketing approval with the EMA for the treatment of vision loss due to Leber congenital amaurosis or retinitis pigmentosa caused by confirmed biallelic RPE65 mutations. Luxturna has received breakthrough therapy and orphan status from the FDA, as well as orphan status from the EMA. Spark’s pipeline also includes SPK-7001 in an ongoing Phase I/II clinical trial for choroideremia.

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and Cowen and Company, LLC, acted as book-running managers for the offering.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023